| Old Articles: <Older 5321-5330 Newer> |
|---|
 |
The Motley Fool
December 18, 2008
Brian Orelli |
Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.   |
The Motley Fool
December 17, 2008
Brian Orelli |
A Super-Cheap Call Option GlaxoSmithKline announces it's partnering up with tiny Dynavax Technologies to develop up to four drugs for autoimmune and inflammatory diseases. The pay-if-the-drug-works scheme should pay off. |
The Motley Fool
December 16, 2008
Brian Orelli |
Doubling Up on Triple Lipid Drugs The Food and Drug Administration gave Abbott Lab's TriLipix the thumbs-up, approving it for use by itself or with statins. |
The Motley Fool
December 16, 2008
Brian Orelli |
Pfizer Keeps the Change For the first time in decades, investors won't get a dividend increase. |
The Motley Fool
December 15, 2008
Brian Orelli |
Medicine Gets a Little More Personal Genetic testing and personalized medicine are still in their infancy, but it's an emerging industry that should be huge in the long run. Which companies stand to benefit from it? |
The Motley Fool
December 15, 2008
Brian Orelli |
A Potentially Game-Changing MS Drug The newest data looks good, but longer studies will be the key for Novartis. |
The Motley Fool
December 12, 2008
Brian Orelli |
A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors. |
The Motley Fool
December 12, 2008
Brian Orelli |
An EXELent Drug Deal Exelixis picks up $195 million in cash in a licensing deal with Bristol-Myers Squibb. |
The Motley Fool
December 12, 2008
Brian Orelli |
Amylin Gets Some FDA Love Amylin's once-weekly diabetes drug Byetta gets a green light from the FDA. |
The Motley Fool
December 12, 2008
Brian Orelli |
The Skinny on the Latest Drug Trial VIVUS' obesity treatment data looks good, but will its drug be a marketing success? |
| <Older 5321-5330 Newer> Return to current articles. |
